Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Braun, M. Bollow, G. Remlinger, U. Eggens, M. Rudwaleit, A. Distler, et al.
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.
Arthritis Rheum, 41 (1998), pp. 58-67
[2.]
J. Brandt, M. Bollow, J. Haberle, M. Rudwaleit, U. Eggens, A. Distler, et al.
Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy.
Rheumatology (Oxford), 38 (1999), pp. 831-836
[3.]
A. Saraux, F. Guillemin, P. Fardellone, P. Guggenbuhl, J.M. Behier, A. Cantagrel, et al.
Agreement between rheumatologist visit and lay interviewer telephone survey for screening for rheumatoid arthritis and spondyloarthropathy.
Joint Bone Spine, 71 (2004), pp. 44-50
[4.]
J.T. Gran, G. Husby, M. Hordvik.
Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, Northern Norway.
Ann Rheum Dis, 44 (1985), pp. 359-367
[5.]
C.S. Lau, R. Burgos-Vargas, W. Louthrenoo, M.Y. Mok, P. Wordsworth, Q.Y. Zeng.
Features of spondyloarthritis around the world.
Rheum Dis Clin North Am, 24 (1998), pp. 753-770
[6.]
M.M. Ward.
Functional disability predicts total costs in patients with ankylosing spondylitis.
Arthritis Rheum, 46 (2002), pp. 223-231
[7.]
A. Boonen, D. Van der Heijde, R. Landewe, A. Spoorenberg, H. Schouten, M. Rutten-van Molken, et al.
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.
Ann Rheum Dis, 61 (2002), pp. 429-437
[8.]
A. Boonen, D. Van der Heijde, R. Landewe, F. Guillemin, A. Spoorenberg, H. Schouten, et al.
Costs of ankylosing spondylitis in three european countries: The patient's perspective.
Ann Rheum Dis, 62 (2003), pp. 741-747
[9.]
A. Boonen, A. Chorus, H. Miedema, D. Van der Heijde, R. Landewe, H. Schouten, et al.
Withdrawal from labour force due to work disability in patients with ankylosing spondylitis.
Ann Rheum Dis, 60 (2001), pp. 1033-1039
[10.]
A. Boonen, A. Chorus, H. Miedema, D. Van der Heijde, H. Van der Tempel, S. Van der Linden.
Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of dutch patients.
Ann Rheum Dis, 60 (2001), pp. 353-358
[11.]
J.L. Severens, J. Mulder, R.J. Laheij, A.L. Verbeek.
Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in the netherlands.
Soc Sci Med, 51 (2000), pp. 243-249
[12.]
A. Zink, J. Braun, J. Listing, J. Wollenhaupt.
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis– results from the German Rheumatological Database. German Collaborative Arthritis Centers.
J Rheumatol, 27 (2000), pp. 613-622
[13.]
E. Roussou, L.G. Kennedy, S. Garrett, A. Calin.
Socioeconomic status in ankylosing spondylitis: relationship between occupation and disease activity.
J Rheumatol, 24 (1997), pp. 908-911
[14.]
F. Guillemin, S. Briancon, J. Pourel, A. Gaucher.
Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors.
Arthritis Rheum, 33 (1990), pp. 1001-1006
[15.]
C. Ramos-Remus, M.A. Macías, M.E. Suárez Almazor.
Labor status and working days lost in a consecutive sample of 103 patients with ankylosing spondylitis.
Arthritis Rheum, 40 (1997), pp. 1392
[16.]
S. Garrett, T. Jenkinson, L.G. Kennedy, H. Whitelock, P. Gaisford, A. Calin.
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.
J Rheumatol, 21 (1994), pp. 2286-2291
[17.]
A. Calin, S. Garrett, H. Whitelock, L.G. Kennedy, J. O’Hea, P. Mallorie, et al.
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.
J Rheumatol, 21 (1994), pp. 2281-2285
[18.]
M. Dougados, A. Gueguen, J.P. Nakache, M. Nguyen, B. Amor.
Evaluation of a functional index for patients with ankylosing spondylitis.
J Rheumatol, 17 (1990), pp. 1254-1255
[19.]
S.D. Jones, A. Steiner, S.L. Garrett, A. Calin.
The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).
Br J Rheumatol, 35 (1996), pp. 66-71
[20.]
The EuroQol group.
EuroQol–A new facility for the measurement of health-related quality of life.
Health Policy, 16 (1990), pp. 199-208
[21.]
C.A. Abbott, P.S. Helliwell, M.A. Chamberlain.
Functional assessment in ankylosing spondylitis: evaluation of a new self-administered questionnaire and correlation with anthropometric variables.
Br J Rheumatol, 33 (1994), pp. 1060-1066
[22.]
M. Mander, J.M. Simpson, A. McLellan, D. Walker, J.A. Goodacre, W.C. Dick.
Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis.
Ann Rheum Dis, 46 (1987), pp. 197-202
[23.]
L. Heuft-Dorenbosch, A. Spoorenberg, A. Van Tubergen, R. Landewe, H. Van ver Tempel, H. Mielants, et al.
Assessment of enthesitis in ankylosing spondylitis.
Ann Rheum Dis, 62 (2003), pp. 127-132
[24.]
S.D. Jones, J. Porter, S.L. Garrett, L.G. Kennedy, H. Whitelock, A. Calin.
A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI).
J Rheumatol, 22 (1995), pp. 1609
[25.]
K. MacKay, C. Mack, S. Brophy, A. Calin.
The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment.
Arthritis Rheum, 41 (1998), pp. 2263-2270
[26.]
A. Calin, K. Mackay, H. Santos, S. Brophy.
A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index.
J Rheumatol, 26 (1999), pp. 988-992
[27.]
M.C. Creemers, M.J. Franssen, M.A. Van’t Hof, F.W. Gribnau, L.B. Van de Putte, P.L. Van Riel.
Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system.
Ann Rheum Dis, 64 (2005), pp. 127-129
[28.]
C. Pacheco-Tena, J.D. Londono, J. Cazarin-Barrientos, A. Martínez, J. Vázquez-Mellado, J.F. Moctezuma, et al.
Development of a radiographic index to assess the tarsal involvement in patients with spondyloarthropathies.
Ann Rheum Dis, 61 (2002), pp. 330-334
[29.]
X. Baraliakos, J. Davis, W. Tsuji, J. Braun.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.
Arthritis Rheum, 52 (2005), pp. 1216-1223
[30.]
W.P. Maksymowych, R.D. Inman, D. Salonen, S.S. Dhillon, R. Krishnananthan, M. Stone, et al.
Spondyloarthritis research consortium of canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis.
Arthritis Rheum, 53 (2005), pp. 502-509
[31.]
H. Marzo-Ortega, D. McGonagle, S. Jarrett, G. Haugeberg, E. Hensor, P. O’Connor, et al.
Infliximab in combination with methotrexate in active ankylosing spondylitis. A clinical and imaging study.
Ann Rheum Dis, 64 (2005), pp. 1568-1575
[32.]
M. Rudwaleit, X. Baraliakos, J. Listing, J. Brandt, J. Sieper, J. Braun.
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis before and during therapy with etanercept.
Ann Rheum Dis, 64 (2005), pp. 1305-1310
[33.]
M. Rudwaleit, X. Baraliakos, J. Listing, J. Brandt, J. Sieper, J. Braun.
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept.
Ann Rheum Dis, 64 (2005), pp. 1305-1310
[34.]
Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford). 2005. En prensa.
[35.]
F. De Keyser, D. Baeten, F. Van den Bosch, E. Kruithof, G. Verbruggen, H. Mielants, et al.
Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
Drugs, 64 (2004), pp. 2793-2811
[36.]
J. Braun, X. Baraliakos, W. Golder, J. Brandt, M. Rudwaleit, J. Listing, et al.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
Arthritis Rheum, 48 (2003), pp. 1126-1136
[37.]
B. Muche, M. Bollow, R.J. Francois, J. Sieper, B. Hamm, J. Braun.
Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging.
Arthritis Rheum, 48 (2003), pp. 1374-1384
[38.]
J. Braun, W. Golder, M. Bollow, J. Sieper, D. Van der Heijde.
Imaging and scoring in ankylosing spondylitis.
Clin Exp Rheumatol, 20 (2002), pp. 178-184
[39.]
H. Marzo-Ortega, D. McGonagle, P. O’Connor, P. Emery.
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study.
Arthritis Rheum, 44 (2001), pp. 2112-2117
[40.]
M. Stone, D. Salonen, M. Lax, U. Payne, V. Lapp, R. Inman.
Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis.
J Rheumatol, 28 (2001), pp. 1605-1614
[41.]
I. Olivieri, L. Barozzi, A. Padula.
Enthesiopathy: clinical manifestations, imaging and treatment.
Baillieres Clin Rheumatol, 12 (1998), pp. 665-681
[42.]
J. Tehranzadeh, R. Kerr, J. Amster.
Magnetic resonance imaging of tendon and ligament abnormalities: Part II. Pelvis and lower extremities.
Skeletal Radiol, 21 (1992), pp. 79-86
[43.]
R.J. Wakefield, D. McGonagle, A.L. Tan, A. Evangelisto, P. Emery.
Ultrasound detection of knee patellar enthesitis.
Ann Rheum Dis, 63 (2004), pp. 753
[44.]
M. Kamel, H. Eid, R. Mansour.
Ultrasound detection of knee patellar enthesitis: a comparison with magnetic resonance imaging.
Ann Rheum Dis, 63 (2004), pp. 213-214
[45.]
M.A. D’Agostino, R. Said-Nahal, C. Hacquard-Bouder, J.L. Brasseur, M. Dougados, M. Breban.
Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study.
Arthritis Rheum, 48 (2003), pp. 523-533
[46.]
P.V. Balint, D. Kane, H. Wilson, I.B. McInnes, R.D. Sturrock.
Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy.
Ann Rheum Dis, 61 (2002), pp. 905-910
[47.]
M.A. D’Agostino, M. Breban, R. Said-Nahal, M. Dougados.
Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound.
Arthritis Rheum, 46 (2002), pp. 840-841
[48.]
W.W. Gibbon, G. Long.
Ultrasound of the plantar aponeurosis (fascia).
Skeletal Radiol, 28 (1999), pp. 21-26
[49.]
D. Van der Heijde, A. Calin, M. Dougados, M.A. Khan, S. Van der Linden, N. Bellamy.
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. progress report of the ASAS working group. assessments in ankylosing spondylitis.
J Rheumatol, 26 (1999), pp. 951-954
[50.]
D. Van der Heijde, S. Van der Linden, M. Dougados, N. Bellamy, A.S. Russell, J. Edmonds.
Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments.
J Rheumatol, 26 (1999), pp. 1003-1005
[51.]
J.J. Anderson, G. Baron, D. Van der Heijde, D.T. Felson, M. Dougados.
Ankylosing spondylitis assessment group preliminary definition of shortterm improvement in ankylosing spondylitis.
Arthritis Rheum, 44 (2001), pp. 1876-1886
[52.]
J. Brandt, J. Listing, J. Sieper, M. Rudwaleit, D. Van der Heijde, J. Braun.
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 1438-1444
[53.]
M. Rudwaleit, J. Listing, J. Brandt, J. Braun, J. Sieper.
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 665-670
[54.]
Zochling J, Van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2005. En prensa.
[55.]
Zochling J, Van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2005. En prensa.
[56.]
J. Braun, M. Bollow, L. Neure, E. Seipelt, F. Seyrekbasan, H. Herbst, et al.
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.
Arthritis Rheum, 38 (1995), pp. 499-505
[57.]
M. Bollow, T. Fischer, H. Reisshauer, M. Backhaus, J. Sieper, B. Hamm, et al.
Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging.
Ann Rheum Dis, 59 (2000), pp. 135-140
[58.]
L. Laloux, M.C. Voisin, J. Allain, N. Martin, L. Kerboull, X. Chevalier, et al.
Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis.
Ann Rheum Dis, 60 (2001), pp. 316-321
[59.]
G. McCormack, D. Moriarty, D.P. O’Donoghue, P.A. McCormick, K. Sheahan, A.W. Baird.
Tissue cytokine and chemokine expression in inflammatory bowel disease.
Inflamm Res, 50 (2001), pp. 491-495
[60.]
D. Baeten, E. Kruithof, L. De Rycke, A.M. Boots, H. Mielants, E.M. Veys, et al.
Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy.
Arthritis Res Ther, 7 (2005), pp. R359-R369
[61.]
E. Kruithof, D. Baeten, L. De Rycke, B. Vandooren, D. Foell, J. Roth, et al.
Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis.
Arthritis Res Ther, 7 (2005), pp. R569-R580
[62.]
D. Baeten, P. Demetter, C. Cuvelier, F. Van Den Bosch, E. Kruithof, N. Van Damme, et al.
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity.
Ann Rheum Dis, 59 (2000), pp. 945-953
[63.]
J. Gu, M. Rihl, E. Marker-Hermann, D. Baeten, J.G. Kuipers, Y.W. Song, et al.
Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles.
J Rheumatol, 29 (2002), pp. 2159-2164
[64.]
J. Brandt, H. Haibel, D. Cornely, W. Golder, J. González, J. Reddig, et al.
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
Arthritis Rheum, 43 (2000), pp. 1346-1352
[65.]
F. Van den Bosch, E. Kruithof, D. Baeten, F. De Keyser, H. Mielants, E.M. Veys.
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
Ann Rheum Dis, 59 (2000), pp. 428-433
[66.]
M. Breban, E. Vignon, P. Claudepierre, V. Devauchelle, D. Wendling, E. Lespessailles, et al.
Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
Rheumatology (Oxford), 41 (2002), pp. 1280-1285
[67.]
E. Collantes-Estévez, M.C. Muñoz-Villanueva, J.D. Cañete-Crespillo, R. Sanmartí-Sala, J. Gratacós-Masmitja, P. Zarco-Montejo, et al.
Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study.
Ann Rheum Dis, 62 (2003), pp. 1239-1240
[68.]
W.P. Maksymowych, G.S. Jhangri, R.G. Lambert, C. Mallon, H. Buenviaje, E. Pedrycz, et al.
Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
J Rheumatol, 29 (2002), pp. 959-965
[69.]
T.I. Temekonidis, Y. Alamanos, S.N. Nikas, D.V. Bougias, A.N. Georgiadis, P.V. Voulgari, et al.
Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study.
Ann Rheum Dis, 62 (2003), pp. 1218-1220
[70.]
S.N. Nikas, Y. Alamanos, P.V. Voulgari, X.I. Pliakou, C.G. Papadopoulos, A.A. Drosos.
Infliximab treatment in ankylosing spondylitis: an observational study.
Ann Rheum Dis, 64 (2005), pp. 940-942
[71.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, et al.
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
Lancet, 359 (2002), pp. 1187-1193
[72.]
J.D. Gorman, K.E. Sack, J.C. Davis Jr.
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
N Engl J Med, 346 (2002), pp. 1349-1356
[73.]
D. Van der Heijde, B. Dijkmans, P. Geusens, J. Sieper, K. DeWoody, P. Williamson, et al.
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
Arthritis Rheum, 52 (2005), pp. 582-591
[74.]
J.C. Davis Jr, D. Van Der Heijde, J. Braun, M. Dougados, J. Cush, D.O. Clegg, et al.
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Arthritis Rheum, 48 (2003), pp. 3230-3236
[75.]
A. Calin, B.A. Dijkmans, P. Emery, M. Hakala, J. Kalden, M. Leirisalo-Repo, et al.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 1594-1600
[76.]
J. Braun, X. Baraliakos, J. Brandt, J. Listing, A. Zink, R. Alten, et al.
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Rheumatology (Oxford), 44 (2005), pp. 670-676
[77.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, G. Burmester, et al.
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
Ann Rheum Dis, 64 (2005), pp. 229-234
[78.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, G. Burmester, et al.
Longterm efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Arthritis Rheum, 48 (2003), pp. 2224-2233
[79.]
J. Davis Jr, A. Webb, S. Lund, K. Sack.
Results from an open-label extension study of etanercept in ankylosing spondylitis.
Arthritis Rheum, 51 (2004), pp. 302-304
[80.]
J.C. Davis Jr, D.M. Van der Heijde, J. Braun, M. Dougados, J. Cush, D. Clegg, et al.
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Ann Rheum Dis, 64 (2005), pp. 1557-1562
[81.]
J. Brandt, J. Listing, H. Haibel, H. Sorensen, A. Schwebig, M. Rudwaleit, et al.
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Rheumatology (Oxford), 44 (2005), pp. 342-348
[82.]
J. Brandt, A. Khariouzov, J. Listing, H. Haibel, H. Sorensen, L. Grassnickel, et al.
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Arthritis Rheum, 48 (2003), pp. 1667-1675
[83.]
X. Baraliakos, J. Listing, J. Brandt, M. Rudwaleit, J. Sieper, J. Braun.
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Arthritis Res Ther, 7 (2005), pp. R439-R444
[84.]
Collantes-Estévez E, Muñoz-Villanueva MC, Zarco P, Torre-Alonso JC, Gratacós J, González C, et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies: an open extension of a multicentre study. Rheumatology (Oxford). 2005. En prensa.
[85.]
H. Schmeling, G. Horneff.
Infliximab in two patients with juvenile ankylosing spondylitis.
Rheumatol Int, 24 (2004), pp. 173-176
[86.]
M. Henrickson, A. Reiff.
Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.
J Rheumatol, 31 (2004), pp. 2055-2061
[87.]
S.M. Tse, R. Burgos-Vargas, R.M. Laxer.
Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
Arthritis Rheum, 52 (2005), pp. 2103-2108
[88.]
J. Braun, X. Baraliakos, J. Listing, J. Sieper.
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the antitumor necrosis factor agents infliximab and etanercept.
Arthritis Rheum, 52 (2005), pp. 2447-2451
[89.]
J.T. Rosenbaum, J.R. Smith.
Anti-TNF therapy for eye involvement in spondyloarthropathy.
Clin Exp Rheumatol, 20 (2002), pp. 143-145
[90.]
E. Rejón, M.D. Giménez, L. Mayordomo, S. Rodríguez, M.P. González, J.L. Marenco.
Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
Scand J Rheumatol, 33 (2004), pp. 323-326
[91.]
D. Baeten, E. Kruithof, F. Van den Bosch, P. Demetter, N. Van Damme, C. Cuvelier, et al.
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.
Arthritis Rheum, 44 (2001), pp. 186-195
[92.]
B. Vandooren, E. Kruithof, D.T. Yu, M. Rihl, J. Gu, L. De Rycke, et al.
Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Arthritis Rheum, 50 (2004), pp. 2942-2953
[93.]
L. De Rycke, B. Vandooren, E. Kruithof, F. De Keyser, E.M. Veys, D. Baeten.
Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of toll-like receptor 2 and toll-like receptor 4 in spondylarthropathy.
Arthritis Rheum, 52 (2005), pp. 2146-2158
[94.]
M.A. Stone, U. Payne, C. Pacheco-Tena, R.D. Inman.
Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 84-87
[95.]
C. Keller, A. Webb, J. Davis.
Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review.
Ann Rheum Dis, 62 (2003), pp. 1128-1132
[96.]
Z. Yin, J. Braun, L. Neure, P. Wu, L. Liu, U. Eggens, et al.
Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis.
Arthritis Rheum, 40 (1997), pp. 1788-1797
[97.]
J. Braun, Z. Yin, I. Spiller, S. Siegert, M. Rudwaleit, L. Liu, et al.
Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis.
Arthritis Rheum, 42 (1999), pp. 2039-2044
[98.]
J.D. Cañete, S.E. Martínez, J. Farres, R. Sanmartí, M. Blay, A. Gómez, et al.
Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies.
Ann Rheum Dis, 59 (2000), pp. 263-268
[99.]
M. Rudwaleit, S. Siegert, Z. Yin, J. Eick, A. Thiel, A. Radbruch, et al.
Low T cell production of TNF-alpha and IFN-gamma in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-308 gene polymorphism.
Ann Rheum Dis, 60 (2001), pp. 36-42
[100.]
J. Braun, J. Xiang, J. Brandt, H. Maetzel, H. Haibel, P. Wu, et al.
Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.
Ann Rheum Dis, 59 (2000), pp. 85-89
[101.]
J. Zou, M. Rudwaleit, J. Brandt, A. Thiel, J. Braun, J. Sieper.
Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Arthritis Rheum, 48 (2003), pp. 780-790
[102.]
J. Zou, M. Rudwaleit, J. Brandt, A. Thiel, J. Braun, J. Sieper.
Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept.
Ann Rheum Dis, 62 (2003), pp. 561-564
[103.]
J.X. Zou, J. Braun, J. Sieper.
Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.
Clin Exp Rheumatol, 20 (2002), pp. 34-37
[104.]
J.Y. Leroux, A. Guerassimov, A. Cartman, N. Delaunay, C. Webber, L.C. Rosenberg, et al.
Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo.
J Clin Invest, 97 (1996), pp. 621-632
[105.]
Y. Zhang, A. Guerassimov, J.Y. Leroux, A. Cartman, C. Webber, R. Lalic, et al.
Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice. evidence for t cell involvement and the immunosuppressive influence of keratan sulfate on recognition of t and b cell epitopes.
J Clin Invest, 101 (1998), pp. 1678-1686
[106.]
R. Burgos-Vargas, J. Rojas-Serrano.
Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis.
J Rheumatol, 32 (2005), pp. 1637-1640
[107.]
J.C. Davis Jr, D. Van der Heijde, M. Dougados, J. Braun, J.J. Cush, D.O. Clegg, et al.
Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
J Rheumatol, 32 (2005), pp. 1751-1754
[108.]
X. Baraliakos, J. Listing, M. Rudwaleit, J. Brandt, J. Sieper, J. Braun.
Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-a antibody infliximab.
Ann Rheum Dis, 64 (2005), pp. 1462-1466
[109.]
D. Baeten, E. Kruithof, F. Van den Bosch, N. Van den Bossche, A. Herssens, H. Mielants, et al.
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?.
Ann Rheum Dis, 62 (2003), pp. 829-834
[110.]
L. De Rycke, D. Baeten, E. Kruithof, F. Van den Bosch, E.M. Veys, F. De Keyser.
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
Arthritis Rheum, 52 (2005), pp. 2192-2201
[111.]
G. Kobelt, P. Andlin-Sobocki, S. Brophy, L. Jonsson, A. Calin, J. Braun.
The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (remicade).
Rheumatology (Oxford), 43 (2004), pp. 1158-1166
[112.]
Boonen A, Van der Heijde D, Severens J, Boendermaker A, Landewe R, Braun J, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared to usual care in patients with active ankylosing spondylitis. Ann Rheum Dis. 2005. En prensa.
[113.]
J. Braun, T. Pham, J. Sieper, J. Davis, S. Van der Linden, M. Dougados, et al.
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.
Ann Rheum Dis, 62 (2003), pp. 817-824
[114.]
Braun J, Davis J, Dougados M, Sieper J, Van der Linden S, Van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2005. En prensa.
[115.]
Panel de Expertos de la Sociedad Española de Reumatología (SER).
Primer documento de consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF-α en las espondiloartritis.
Reumatol Clin, 1 (2005), pp. 32-37
[116.]
M. Temel, P. Atagunduz, H. Direskeneli.
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require antitumour necrosis factor {alpha} biological treatments according to the current guidelines.
Ann Rheum Dis, 64 (2005), pp. 1383-1384
[117.]
N. Barkham, K.O. Kong, A. Tennant, A. Fraser, E. Hensor, A.M. Keenan, et al.
The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Rheumatology (Oxford), 44 (2005), pp. 1277-1281
Copyright © 2005. Elsevier España S.L. Barcelona
